Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone

Psychoneuroendocrinology

Volumn 31, Issue 10, 2006, Pages 1208-1219

  Klatzkin, Rebecca R ^a   Leslie Morrow, A ^a   Light, Kathleen C ^a   Pedersen, Cort A ^a   Girdler, Susan S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Allopregnanolone; Depression; PMDD; Progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; PROGESTERONE;

ADULT; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FATIGUE; FEMALE; HUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AFFECT; CAPSULES; CROSS-OVER STUDIES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PLACEBOS; PREGNANOLONE; PREMENSTRUAL SYNDROME; PROGESTERONE; TIME FACTORS;

EID: 33751224171     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2006.09.002     Document Type: Article

References (41)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (1994), American Psychiatric Association, Washington, DC
2. Andreen L., Sundstrom-Poromaa I., Bixo M., Andersson A., Nyberg S., and Backstrom T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30 (2005) 212-224
3. Barbaccia M.L., Concas A., Serra M., and Biggio G. Stress and neurosteroids in adult and aged rats. Exp. Gerontol. 33 (1998) 697-712
4. Benassayag C., Souski I., Mignot T.M., Robert B., Hassid J., Duc-Goiran P., Mondon F., Rebourcet R., Dehennin L., Nunez E.A., and Ferre F. Corticosteroid-binding globulin status at the fetomaternal interface during human term pregnancy. Biol. Reprod. 64 (2001) 812-821
5. A receptors. Eur. J. Pharmacol. 325 (1997) 1-7
6. Cohen L.S., Soares C.N., Otto M.W., Sweeney B.H., Liberman R.F., and Harlow B.L. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The harvard study of moods and cycles. J. Affect. Disord. 70 (2002) 125-132
7. Dunn J.F., Nisula B.C., and Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53 (1981) 58-68
8. Ehnvall A., Sjogren M., and Zachrisson H.A. HPA activation determined by the CRH challenge test in patients with few versus multiple episodes of treatment-refractory depression. Eur. Arch. Psychiatry. Clin. Neurosci. 254 (2004) 349-355
9. Endicott J., Amsterdam J., Eriksson E., Frank E., Freeman E., Hirschfeld R., Ling F., Parry B., Pearlstein T., Rosenbaum J., Rubinow D., Schmidt P., Severino S., Steiner M., Stewart D.E., and Thys-Jacobs S. Is premenstrual dysphoric disorder a distinct clinical entity?. J. Womens Health Gend. Based Med. 8 (1999) 663-679
10. Epperson C.N., Haga K., Mason G.F., Sellers E., Gueorguieva R., Zhang W., Weiss E., Rothman D.L., and Krystal J.H. Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder. Arch. Gen. Psychiatry 59 (2002) 851-858
11. Freeman E.W., Weinstock L., Rickels K., Sondheimer S.J., and Coutifaris C. A placebo-controlled study of effects of oral progesterone on performance and mood. Br. J. Clin. Pharmacol. 33 (1992) 293-298
12. Frye C.A., and Walf A.A. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm. Behav. 41 (2002) 306-315
13. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., and Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psychiatry 49 (2001) 788-797
14. Guo A.L., Petraglia F., Criscuolo M., Ficarra G., Nappi R.E., Palumbo M.A., Trentini G.P., Purdy R.H., and Genazzani A.R. Evidence for a role of neurosteroids, in modulation of diurnal changes and acute stress-induced corticosterone secretion in rats. Gynecol. Endocrinol. 9 (1995) 1-7
15. Hallman J. The premenstrual syndrome-an equivalent of depression?. Acta Psychiatr. Scand. 73 (1986) 403-411
16. Hammarback S., Damber J.E., and Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J. Clin. Endocrinol. Metab. 68 (1989) 125-130
17. Hurt S.W., Schnurr P.P., Severino S.K., Freeman E.W., Gise L.H., Rivera-Tovar A., and Steege J.F. Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints. Am. J. Psychiatry 149 (1992) 525-530
18. Janis G.C., Devaud L.L., Mitsuyama H., and Morrow A.L. Effects of chronic ethanol consumption and withdrawal on the neuroactive steroid 3alpha-hydroxy-5alpha-pregan-20-one in male and female rats. Alcohol Clin. Exp. Res 22 (1998) 2055-2061
19. Kendler K.S., Karkowski L.M., Korey L.A., and Neale M.C. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am. J. Psychiatry 155 (1998) 1234-1240
20. Kirschbaum C., Pirke K.M., and Hellhammer D.H. The 'Trier Social Stress Test'-a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28 (1993) 76-81
21. Klatzkin R.R., Morrow A.L., Light K.C., Pedersen C.A., and Girdler S.S. Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women. Biol. Psychol. 71 (2005) 2-11
22. Lombardi I., Luisi S., Quirici B., Monteleone P., Bernardi F., Liut M., Casarosa E., Palumbo M., Petraglia F., and Genazzani A.R. Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome. Gynecol. Endocrinol. 18 (2004) 79-87
23. McAuley J.W., Kroboth F.J., and Kroboth P.D. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 16 (1996) 453-457
24. Mechlin B., Morrow A.L., Maixner W., and Girdler S.S. Allopregnanolone, Ethnicity, and Pain Sensitivity. Psychosom. Med. 68 (2006) A28
25. Miczek K.A., Fish E.W., and DeBold J.F. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm. Behav. 44 (2003) 242-257
26. Monteleone P., Luisi S., Tonetti A., Bernardi F., Genazzani A.D., Luisi M., Petraglia F., and Genazzani A.R. Allopregnanolone concentrations and premenstrual syndrome. Eur. J. Endocrinol. 142 (2000) 269-273
27. Morrow A.L., Pace J.R., Purdy R.H., and Paul S.M. Characterization of steroid interactions with g-aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroid recognition sites. Mol. Pharmacol. 37 (1990) 263-270
28. Morrow A.L., Suzdak P.D., and Paul S.M. Steroid hormone metabolities potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. Eur. J. Pharmacol. 142 (1987) 483-485
29. Paul S.M., and Purdy R.H. Neuroactive steroids. FASEB J 6 (1992) 2311-2322
30. Pruessner J.C., Kirschbaum C., Meinlschmid G., and Hellhammer D.H. Two formulas for computation of area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28 (2003) 916-931
31. Purdy R.H., Morrow A.L., Blinn J.R., and Paul S.M. Synthesis, metabolism, and pharmacological activity of 3a-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes. J. Med. Chem. 33 (1990) 1572-1581
32. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., and Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90 (1997) 709-714
33. Reid R.L. Premenstrual syndrome. In: Leventhal J.M., Hoffman J.J., Keith L.G., and Taylor P.H. (Eds). Obstetrics, Gynecology and Fertility (1985), Year Book Medical Publishers, Chicago
34. Romeo E., Strohle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., and Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155 (1998) 910-913
35. Rubinow D.R., Schmidt P.J., and Roca C.A. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol. Bull. 34 (1998) 289-290
36. Schmidt P.J., Purdy R.H., Moore Jr. P.H., Paul S.M., and Rubinow D.R. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab. 79 (1994) 1256-1260
37. Strohle A., Pasini A., Romeo E., Hermann B., Spalletta G., di Michel F., Holsboer F., and Rupprecht R. Fluoxetine decreases concentrations of 3α, 5α-tetrahydrodeoxycorticosterone (THDOC) in major depression. J. Psychiatr. Res. 34 (2000) 183-186
38. Sundstrom I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., and Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67 (1998) 126-138
39. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., and Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA 95 (1998) 3239-3244
40. Uzunova V., Wrynn A.S., Kinnunen A., Ceci M., Kohler C., and Uzunov D.P. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol. 486 (2004) 31-34
41. Wang M., Seippel L., Purdy R.H., and Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J. Clin. Endocrinol. Metab. 81 (1996) 1076-1081